Article Information
History
- May 30, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Effat Davoudi-Monfared1,
- Hamid Rahmani2,
- Hossein Khalili3,*,
- Mahboubeh Hajiabdolbaghi4,
- Mohamadreza Salehi5,
- Ladan Abbasian6,
- Hossein Kazemzadeh7 and
- Mir Saeed Yekaninejad8
- 1Department of Pharmacotherapy, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran, edavudimonfared{at}gmail.com
- 2Department of Pharmacotherapy, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran, hmdrahmani89{at}gmail.com
- 3Department of Pharmacotherapy, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran, khalilih{at}tums.ac.ir
- 4Department of Infectious Diseases, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran, mahboubeh1591{at}gmail.com
- 5Department of Infectious Diseases, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran, salehi.mohamad3{at}gmail.com
- 6Department of Infectious Diseases, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran, la.abbasian{at}gmail.com
- 7Advance Thoracic Research Center, Occupational Sleep Research Center, Tehran University of Medical Sciences, Tehran, Iran, Hokkazemizadeh{at}gmail.com
- 8Department of Epidemiology and Biostatistics, School of Public health, Tehran University of Medical Sciences, Tehran, Iran, yekaninejad{at}yahoo.com
- ↵*Corresponding Author Hossein Khalili, Professor of Pharmacotherapy, Department of Pharmacotherapy, Tehran University of Medical Sciences, Tehran, Iran. Postal Code: 1417614411 P.O.Box: 14155/6451 Tel/Fax: +98-21-66954709 E-mail: Khalilih{at}sina.tums.ac.ir
Posted May 30, 2020.
Efficacy and safety of interferon β-1a in treatment of severe COVID-19: A randomized clinical trial
